Patents by Inventor Da Na JEONG

Da Na JEONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11713308
    Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: August 1, 2023
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Eui Chul Lee, Sol Park, Hyok Jun Cho, Cheol Hee Lim, So Young Kim, Hyun Ho Choi, Da Na Jeong, Na Yeon Yang, Na Ry Ha
  • Publication number: 20230044255
    Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Application
    Filed: July 6, 2021
    Publication date: February 9, 2023
    Inventors: Tae Dong HAN, Hee Jae TAK, Eun Kyung KIM, Eui Chul LEE, Sol PARK, Hyok Jun CHO, Cheol Hee LIM, So Young KIM, Hyun Ho CHOI, Da Na JEONG, Na Yeon YANG, Na Ry HA
  • Patent number: 11168073
    Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: November 9, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Eui Chul Lee, Sol Park, Hyok Jun Cho, Cheol Hee Lim, So Young Kim, Hyun Ho Choi, Da Na Jeong, Na Yeon Yang, Na Ry Ha
  • Publication number: 20200223827
    Abstract: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Application
    Filed: December 12, 2019
    Publication date: July 16, 2020
    Inventors: Tae Dong HAN, Hee Jae TAK, Eun Kyung KIM, Eui Chul LEE, Sol PARK, Hyok Jun CHO, Cheol Hee LIM, So Young KIM, Hyun Ho CHOI, Da Na JEONG, Na Yeon YANG, Na Ry HA